- Several Potential Catalysts Expected in Next Six Months -
BRISBANE, Calif., July 31 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced results from operations for the second quarter and six months ended June 30, 2008. InterMune reported a net loss for the second quarter of 2008 of $26.5 million, or $0.68 per share, compared with a net loss of $19.8 million, or $0.58 per share, in the second quarter of 2007.
Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "The second quarter of 2008 was an exciting period for InterMune. We reported substantial progress on our collaboration with Roche with ITMN-191 (R7227) by reporting top-line results from our 14-day monotherapy study, reporting the successful completion of 13-week preclinical toxicology studies in two species that enable our Phase 2 studies and announcing the initiation of our 14-day study of ITMN-191 plus standard of care therapy."
Mr. Welch continued, "The next six months will be a very rich period in terms of data and milestones for InterMune. At the AASLD meeting in late October, we expect to present the results of our two completed clinical studies of ITMN-191 as well as the results of non-clinical studies of ITMN-191 in combination with direct antiviral compounds in the Roche portfolio. During the fourth quarter, we expect to announce top-line results from our on-going 14-day study of ITMN-191 plus standard of care therapy and in January of 2009, we expect to report top-line results from our Phase 3 CAPACITY program for pirfenidone in idiopathic pulmonary fibrosis, a fatal disease for which no treatments are approved."
Results for Second Quarter 2008
InterMune reported total revenue in the s
|SOURCE InterMune, Inc.|
Copyright©2008 PR Newswire.
All rights reserved